eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | thrombocytopenia |
| Comorbidity | C0026986|myelodysplastic syndrome |
| Sentences | 9 |
| PubMedID- 25632241 | Giagounidis et al reported the results of a comparison of romiplostim and placebo for treatment of thrombocytopenia in patients with myelodysplastic syndrome.72 despite promising results showing increased platelet counts, decreased number of bleeding events, and decreased platelet transfusions in the romiplostim arm, the study was discontinued early due to concerns of excess blasts and the rate of aml. |
| PubMedID- 25659186 | thrombocytopenia in patients with myelodysplastic syndromes (mds) is a frequent cause of haemorrhage-related morbidity and mortality, and is associated with increased risk of leukaemic transformation and reduced overall survival. |
| PubMedID- 23403320 | Plasma thrombopoietin levels were measured in 120 patients who had myelodysplastic syndrome with thrombocytopenia (< 100 x 10(9)/l) to determine any correlation to markers associated with immune pathophysiology and outcome. |
| PubMedID- 21575929 | Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. |
| PubMedID- 20620439 | thrombocytopenia in patients with myelodysplastic syndromes. |
| PubMedID- 22129476 | Platelet associated igg may be related with thrombocytopenia in patients with myelodysplastic syndromes. |
| PubMedID- 24706489 | Background: thrombocytopenia in patients with myelodysplastic syndrome (mds) is associated with shortened survival and an increased risk of evolution to acute myeloid leukemia (aml). |
| PubMedID- 22967412 | Objective: to investigate the prognostic value of thrombocytopenia in patients with primary myelodysplastic syndromes (mds). |
| PubMedID- 23190430 | Background: lenalidomide treatment in myelodysplastic syndrome (mds) may lead to thrombocytopenia and dose reductions/delays. |
Page: 1